Gressin, R., Daguindau, N., Tempescul, A., Moreau, A., Carras, S., Tchernonog, E., Schmitt, A., Houot, R., Dartigeas, C., Pignon, J. M., Corm, S., Banos, A., Mounier, C., Dupuis, J., Macro, M., Fleury, J., Jardin, F., Sarkozy, C., Damaj, G., Feugier, P., Fornecker, L. M., Chabrot, C., Dorvaux, V., Bouadallah, K., Amorin, S., Garidi, R., Voillat, L., Joly, B., Celigny, P. S., Morineau, N., Moles, M. P., Zerazhi, H., Fontan, J., Arkam, Y., Alexis, M., Delwail, V., Vilque, J. P., Ysebaert, L., Le Gouill, S., Callanan, M. B. and for the Lymphoma Study Association (2018) “A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma”, Haematologica. Pavia, Italy, 104(1), pp. 138-146. doi: 10.3324/haematol.2018.191429.